Find uplifting stories about heroes, innovations, and solutions
144 results for "btk inhibitor"
A new multiple sclerosis treatment from Novartis has achieved positive results in clinical trials, offering fresh hope to millions living with this challenging autoimmune disease. The BTK inhibitor represents a promising advance in MS care.
A new combination therapy for aggressive prostate cancer just got FDA approval, along with two tests that help doctors match the right patients to this targeted treatment. This breakthrough could help up to 30% of men with advanced prostate cancer find a treatment plan designed specifically for their genes.
Mount Sinai researchers discovered that severe anemia in cancer patients taking PARP inhibitors often stems from a treatable folate deficiency, not unavoidable side effects. A simple folic acid supplement could help thousands stay on life-saving treatment.
More than a million breast cancer patients have benefited from CDK inhibitors, and researchers at Roswell Park are now working to extend these life-saving benefits to other cancer types. New drug combinations and precision medicine approaches could help more patients live longer with fewer side effects.
After decades of slow progress, breakthrough drugs targeting a genetic mutation found in 90% of pancreatic cancers are nearing FDA approval in 2026. The KRAS inhibitors now in late-stage trials could transform treatment for one of medicine's deadliest diseases.
The FDA just approved Beqalzi, the first BCL2 inhibitor for patients with relapsed mantle cell lymphoma who've tried other treatments. Over half the patients in trials responded to the new therapy, offering fresh hope for those with limited options.
British researchers discovered why identical cancer treatments work brilliantly for some patients but fail others. The breakthrough could help doctors personalize therapies and save thousands of lives.
Researchers discovered a way to make treatment-resistant cancer cells vulnerable again by breaking down their DNA repair machinery. The breakthrough could help millions of patients whose cancers stopped responding to existing therapies.
After taking a common blood pressure drug for a decade without problems, Lily woke up with a swollen face and learned at the ER that rare reactions can happen years later. Her story is helping thousands understand an unexpected medication risk.
Scientists discovered that a common diabetes medication protects aging kidneys by keeping blood vessels healthy and reducing inflammation. The breakthrough came from studying tiny fish that age in just months, letting researchers witness decades of organ aging in weeks.
Scientists discovered how a widely prescribed diabetes drug protects aging kidneys by studying a fish that lives just four months. The breakthrough could help millions keep their kidneys healthier as they age.
Millions who take daily heartburn medication can breathe easier after a massive 26-year study across five countries found no link between long-term use and stomach cancer. The research finally puts to rest decades of anxiety for patients who depend on these drugs.
A breakthrough drug called daraxonrasib is giving hope to pancreatic cancer patients after scientists spent nearly 50 years trying to target the KRAS mutation. Patients like 36-year-old Leanna Stokes are living far longer than expected thanks to this medical breakthrough.
Millions managing stubborn high cholesterol just got a breakthrough option that doesn't require needles. The FDA approved the world's first oral pill that works as powerfully as injections, offering new hope for patients who struggle to lower dangerous cholesterol levels.
A new triple therapy treatment completely eliminated pancreatic tumors in mice, offering hope for one of the deadliest cancers. The breakthrough could transform treatment for the 67,000 Americans diagnosed each year.
Scientists at Duke University discovered a moment when cancer cells become vulnerable during their shapeshifting process. This breakthrough could lead to more effective treatments that stop cancer from spreading and surviving therapy.
A breakthrough drug called daraxonrasib targets the "undruggable" mutation behind 90% of pancreatic cancers, nearly doubling survival time in a major clinical trial. Patients lived 13.2 months compared to 6.7 months with standard chemotherapy.
University of Pennsylvania researchers eliminated precancerous pancreatic cells in mice before they became tumors, nearly doubling survival time. It's the first proof that medical intervention can stop pancreatic cancer at its earliest stage.
A drug that flopped in Alzheimer's trials just helped obese mice lose 20% of their body weight without eating less or exercising more. Johns Hopkins researchers are now testing whether this accidental discovery could help millions of people struggling with severe obesity.
Showing 20 of 144